CombiMatrix Reiterates Previously Reported Terms of Nasdaq Listed Warrants (Symbol: CBMXW)

CombiMatrix Reiterates Previously Reported Terms of Nasdaq Listed Warrants (Symbol: CBMXW)  IRVINE, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Due to recent trading activity in CombiMatrix Corporation's (Nasdaq:CBMX) publicly listed warrants, symbol CBMXW, the Company would like to reiterate the terms of said warrants.   These warrants, originally issued in April 2009 and as adjusted pursuant to their terms by the reverse split of the Company's common stock and warrants previously announced on December 4, 2012, currently have an exercise price of $90.00 and will expire on May 1, 2014 if not exercised by such time.  About CombiMatrix Corporation  CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care – specializing in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers comprehensive testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies.The Company performs genetic testing utilizing microarray, FISH, PCR and G-Band chromosome analyses. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.  CONTACT: Company Contact:          Mark McDonough          President & CEO, CombiMatrix Corporation          Tel (949) 753-0624                   Investor Relations / Media Contact:          Rene Caron          Partner          Allen & Caron, Inc.          Tel (949) 474-4300          rene@allencaron.com  CombiMatrix Corporation